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Abstract 
As the Sars-CoV2 pandemic continues to grow, researchers around the world 
are urgently seeking new treatments to prevent infection, cure those infected, 
or lessen the severity of the disease. Although there are several recently 
approved vaccines, clinical trials are underway to "re-use" drugs normally 
indicated for other diseases. This teaching experience studies the market for 8 
pharmaceutical products used to fight the pandemic (remdesivir, favipiravir, 
lopinavir/ritonavir, chloroquine, hydroxychloroquine, sofosbuvir, pyrfenidone 
and tocilizumab) in 13 countries (Bangladesh, Brazil, China, Egypt, France, 
India, Malaysia, Pakistan, South Africa, Sweden, Turkey, United Kingdom and 
United States). Through the analysis of prices and costs, we reflect on the 
difficulty of access to treatment according to the country.The objective is to 
deepen knowledge of the pharmaceutical market: (i) to demonstrate in a 
tangible way the differences between production costs and final prices of 
medicines, (ii) to perceive the difficulty of access to certain treatments 
depending on the country, (iii) to reflect on what initiatives should be 
implemented in an international emergency context such as the one we are 
experiencing.  
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As the Sars-CoV2 pandemic continues to grow, researchers around the world are urgently 
seeking new treatments to prevent infection, cure those infected, or lessen the severity of the 
disease. As of 9 January 2021, 87.5 million cases have been confirmed and 1.9 million people 
have died. Although there are several recently approved vaccines, clinical trials are underway 
to "re-use" drugs normally indicated for other diseases (Li and LeClercq, 2020). The shorter 
development time and reduced costs of using existing compounds are particularly 
advantageous compared to the discovery of new drugs in a pandemic situation, where time 
is of the essence.  
Antiviral drugs include the nucleotide analogue remdesivir, which was previously used 
experimentally but without success against Ebola (Siegal et al, 2017), favipiravir, used to 
treat influenza (Hayden and Shindo, 2019), the HIV protease inhibitor lopinavir/ritonavir 
(Cao et al., 2020), the antimalarials chloroquine and hydroxychloroquine (Yao et al., 2020), 
and the direct-acting antivirals sofosbuvir and daclatasvir (IRCT, 2020). In addition, 
treatments to improve lung function and reduce inflammation, such as pyrfenidone (WIPO, 
2017) and tocilizumab (ClinicalTrials.gov, 2020), are being evaluated in clinical trials.  
Most of the clinical trials reported so far are small pilot studies, often non-randomised, 
making interpretation of the current evidence difficult. If the results of these new trials are 
favourable, there is a possibility of rapidly increasing the production of the most promising 
drugs. Low- and middle-income countries will need access to these treatments at minimum 
prices to ensure that all who need them can be treated.  Even in high-income countries, the 
disease burden could be so great that access to medicines at minimal cost may also be 
necessary. The HIV epidemic has been controlled by mass treatment with antiretroviral drugs 
around the world at very low unit cost. Large donor organizations, such as the Global Fund 
to Fight Immunodeficiency, Tuberculosis and Malaria and the United States President's 
Emergency Plan for Immunodeficiency Relief, are ordering drugs to treat more than 20 
million people with HIV, at prices close to the cost of production (PEPFAR, 2019; The 
Global Fund, 2020). This system enables low- and middle-income countries to access high-
quality drugs at affordable prices.  
This educational project is designed for students in Economics, Business Administration, 
Political Science and Sociology. The objective is to deepen knowledge of the pharmaceutical 
market: (i) to demonstrate in a tangible way the differences between production costs and 
final prices of medicines, (ii) to perceive the difficulty of access to certain treatments 
depending on the country, (iii) to reflect on what initiatives should be implemented in an 
international emergency context such as the one we are experiencing. This will be done by 
consulting statistical bases and reading support documents on the structure of the 
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pharmaceutical market. It is better to develop this practice in small groups and then share it 
in order to favour "withing groups" and "between groups" interactions.  
2. Preparation of price and cost information 
The minimum production costs of medicines can be estimated by calculating the cost of 
active pharmaceutical ingredients, which is combined with the costs of excipients, 
formulation, packaging and a profit margin to estimate the price of the 'finished product', i.e. 
the ready-to-use medicine (Hill et al., 2018).  Table 1 shows, for each drug, the duration of 
treatment and the number of doses to be administered each day, the daily cost of treatment 
and the total cost.  
Table 1. Characteristics of each drug. Daily cost and total cost. 






Remdesivir 10 days 2 the 1st day; 1 other days 9 0,93 
Favipiravir 14 days 2 per day 20 1,45 
Lopinavir 14 days 2 per day 4 0,28 
Hidroxcicloroquina 14 days 1 per day 1 0,08 
Cloroquina 14 days 1 per day 0,3 0,02 
Azitromicina 14 days 1 per day 1,4 0,2 
Sofosvubir 14 days 1 per day 5 0,39 
Pirfenidone 28 days 3 per day 31 1,09 
Tocilizumab - 2 177,5 355 
Source: Own work using data from Hill et al. (2020). For Tocilizumab the table has been completed using 
information from  Table 1, Cost-Comparison Table for Biologic Disease-Modifying Drugs for Rheumatoid Arthritis 
- Tocilizumab (Actemra) - NCBI Bookshelf (nih.gov). 
Price information was obtained through published lists for each medicine in a number of 
countries (Bangladesh, Brazil, China, Egypt, France, India, Malaysia, Pakistan, South Africa, 
Sweden, Turkey, United Kingdom and United States) to provide a representative sample of 
prices in countries with different levels of economic development, although all the medicines 
analysed in this study are available in the selected countries. Where more than one price was 
available for the same medicine, the lowest price was chosen. Table 2 shows the price of full 
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Bangladesh 600 - - 3 0,2 5 168 124 690 
Brazil 600 - - - - 19 4289 - - 
China 600 231 17 19 5 7 - 1379 1.950 
Egypt 600 - - - - - - - 606 
United States 3.120 - 503 18 93 63 18610 9.606 3.383 
France 2.340 - 97 5 - 44 - 2.344 - 
India 600 112,8 40 2 1 5 7 100 806 
Malasya 600 - - 7 2 11 - - - 
Pakistan 600 - - - - - 6 - 510 
United Kingdom 2.340 - 144 4 8 11 7832 2.561 914 
South Africa 600 - 15 - 5 35 - 2.490 566 
Sweden 2.340 - 172 3 4 16 - 2.196 - 
Turkey 600 - 149 3 - - - 1.499 650 
Source: Hill et al. (2020). For remdesivir and favipiravir, information has been completed using Remdesivir 
developed country price announced | Medicines Law & Policy (medicineslawandpolicy.org)  y India's 
Glenmark cuts price of COVID-19 drug favipiravir version to $1 per tablet | Reuters. Price for treatment 
with remdesivir was 600$ in developing countries, 2.340$ in developed countries and 3.120 in United 
States. 
3. Content of the practice 
The practice begins with the reading of two documents: "Patents, price regulation and 
innovation in the pharmaceutical industry" and "Drug price differentials across different 
retail market settings", both available on the internet (see references).  After this reading, the 
following introductory questions are posed:  
1. What special characteristics differentiate medicines from other goods? 
2. What type of market do you consider to be the pharmaceutical market? 
3. Does it share characteristics with a market of perfect competition? Given your 
answer to this question, do you consider that there may be a market failure in the 
pharmaceutical market? 
4. What are the advantages and disadvantages of pharmaceutical patents? 
5. Do you consider that the knowledge on which new pharmaceutical products are 
based is a public good? 
6. With the information in tables 1 and 2, a series of exercises are proposed. 
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Mean 1,195.38 171.90 142.13 7.11 14.78 21.60 5,152.00 2,477.67 1,119.44 
SD 949.78 68.92 140.72 6.40 25.35 19.36 5,420.58 2,602.49 947.38 
Source: Own work 
• There are medicines with a very low average price (hydroxychloroquine, 
chloroquine and azithromycin), but there are also very expensive ones (remdesivir, 
pirfenidone, sofosvubir). 
• Within a single drug, there is also wide variability between countries (perfenidone, 
tociluzumab). 
Exercise 2: Calculate the mark-up ratio for each drug and each country, taking into account 
the price and cost data for the entire treatment. Also calculate the mean and standard deviation 
of the mark-up ratio for each drug: 
𝑀𝑎𝑟𝑘 − 𝑢𝑝	𝑟𝑎𝑡𝑖𝑜	 =
𝑃𝑟𝑖𝑐𝑒 −𝑀𝑎𝑟𝑔𝑖𝑛𝑎𝑙	𝑐𝑜𝑠𝑡
𝑀𝑎𝑟𝑔𝑖𝑛𝑎𝑙	𝑐𝑜𝑠𝑡  






























































Bangladesh 65.67 - - 2.00 -0.33 2.57 32.60 3.00 0.94 
Brazil 65.67 - - - - 12.57 856.80 - - 
China 65.67 10.55 3.25 18.00 15.67 4.00 - 43.48 4.49 
Egypt 65.67 - - - - - - - 0.71 
United States 345.67 - 124.75 17.00 309.00 44.00 3,721.00 308.87 8.53 
France 259.00 - 23.25 4.00 - 30.43 - 74.61 - 
India 65.67 4.64 9.00 1.00 2.33 2.57 0.40 2.23 1.27 
Malasya 65.67 - - 6.00 5.67 6.86 - - - 
Pakistan 65.67 - - - - - 0.20 - 0.44 
U. Kingdom 259.00 - 35.00 3.00 25.67 6.86 1,565.40 81.61 1.57 
South Africa 65.67 - 2.75 - 15.67 24.00 - 79.32 0.59 
Sweden 259.00 - 42.00 2.00 12.33 10.43 - 69.84 - 
Turkey 65.67 - 36.25 2.00 - - - 47.35 0.83 
Mean 131.82 7.60 34.53 6.11 48.25 14.43 1,029.40 78.92 2.15 
SD 105.53 3.10 34.92 6.15 84.34 13.62 1,083.86 83.73 2.43 
Source: Own work 
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• The lowest profit margin corresponds to tocilizumab, favipiravir, 
hydroxychloroquine and azithromycin. 
• The highest profit margin corresponds to sofosvubir. 
Exercise 3: Find the GDP per capita for each country (e.g. World Bank statistics) and 
compare the price of the full treatment with the GDP per capita of each country.  









































































Bangladesh 1,855.7 32.33 - - 0.16 0.01 0.27 9.05 6.68 37.18 
Brazil 8,717.2 6.88 - - - - 0.22 49.20 - - 
China 10,261.7 5.85 2.25 0.17 0.19 0.05 0.07 - 13.44 19.00 
Egypt 3,019.2 19.87 - - - - - - - 20.07 
United States 65,297.5 4.78 - 0.77 0.03 0.14 0.10 28.50 14.71 5.18 
France 40,493.9 5.78 - 0.24 0.01 - 0.11 - 5.79 - 
India 2,099.6 28.58 5.37 1.91 0.10 0.05 0.24 0.33 4.76 38.39 
Malasya 11,414.2 5.26 - - 0.06 0.02 0.10 - - - 
Pakistan 1,284.7 46.70 - - - - - 0.47 - 39.70 
U.Kingdom 42,330.1 5.53 - 0.34 0.01 0.02 0.03 18.50 6.05 2.16 
South Africa 6,001.4 10.00 - 0.25 - 0.08 0.58 - 41.49 9.43 
Sweden 51,615.0 4.53 - 0.33 0.01 0.01 0.03 - 4.25 - 
Turkey 9,126.6 6.57 - 1.63 0.03 - - - 16.42 7.12 
Source: Own work using data from GDP per capita (current US$) | Data (worldbank.org). 
• Treatment with some drugs is relatively expensive compared to the country's 
GDPpc: remdesivir accounts for 28% in India, 32% of GDPpc in Bangladesh, 46% 
in Pakistan; pirfenidone accounts for 16% in Turkey and 41% in South Africa. 
Exercise 4: Look at public health expenditure per capita (e.g. World Bank statistics) and 
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Bangladesh 7.12 8,426.97 - - 42.13 2.81 70.22 2,359.55 1,741.57 9,691.01 
Brazil 353.54 169.71 - - - - 5.37 1,213.16 - - 
China 282.68 212.25 81.72 6.01 6.72 1.77 2.48 - 487.83 689.83 
Egypt 36.07 1,663.43 - - - - - - - 1,680.07 
United States 5,355.79 58.25 - 9.39 0.34 1.74 1.18 347.47 179.36 63.17 
France 3,441.17 68.00 - 2.82 0.15 - 1.28 - 68.12 - 
India 19.63 3,056.55 574.63 203.77 10.19 5.09 25.47 35.66 509.42 4,105.96 
Malasya 218.65 274.41 - - 3.20 0.91 5.03 - - - 
Pakistan 15.24 3,937.01 - - - - - 39.37 - 3,346.46 
U.Kingdom 3,392.09 68.98 - 4.25 0.12 0.24 0.32 230.89 75.50 26.95 
South Africa 284.28 211.06 - 5.28 - 1.76 12.31 - 875.90 199.10 
Sweden 5,089.96 45.97 - 3.38 0.06 0.08 0.31 - 43.14 - 
Turkey 301.69 198.88 - 49.39 0.99 - - 0.00 496.87 215.45 
Source: Own work using data from Domestic general government health expenditure per capita (current US$) | 
Data (worldbank.org). 
• The unaffordability of some of the treatments becomes even more apparent when 
comparing their price with public health expenditure. In India, the cheapest 
treatment is 5 times the public health expenditure in per capita terms. In Sweden, 
some treatments account for a tiny percentage of public health expenditure 
(hydroxychloroquine, chloroquine, azithromycin), but others account for more than 
40% of public expenditure per capita (remdesivir, pirfenidone).  
• Few drugs are marketed in some countries, which means that there are very few 
options to choose from. In Pakistan, the cost of treatment ranges from 39 to 3,000%, 
in Brazil it ranges from 5 to 1,200%. 
• The differences between tables 5 and 6 highlight that GDP per capita is not an 
"ideal" indicator of economic well-being. In countries with low GDP per capita, 
public expenditure on health is even lower and this may make it impossible for the 
public health system to purchase medicines to combat the coronavirus. 
Exercise 5: Reflect on the above results and suggest some measures that could improve 
affordability and access to treatment. 
• This analysis shows that medicines to treat cOViD-19 could be manufactured at 
very low prices. If promising results from key clinical trials emerge, there is a 
possibility to increase production of generics and provide treatment to millions of 
people at very low unit prices.   
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• Large orders are needed to encourage generic companies to manufacture medicines 
at low prices, as is the case for AIDS, malaria and TB medicines.  
• Other mechanisms are in place to optimise drug manufacturing. With joint 
procurement, a number of countries can order medicines together, to take advantage 
of economies of scale. There can be volume-price guarantees to purchase large 
quantities of medicines at fixed prices for a certain number of years.  
• Prequalification of major companies by the WHO can be recognized by any country 
as an indicator of the quality of the medicine, including adherence to good 
manufacturing practices and the stability or viability of the medicine over its stated 
shelf life, along with the bioequivalence of generic to branded versions. 
• We need open 'technology transfer' so that the methods used to manufacture key 
medicines can be shared with any country that decides to produce them locally. 
4. Conclusion and recommedations 
This teaching experience has been very satisfactory, both from the point of view of the 
students' involvement and work, as well as their own assessment of the subject studied. In 
the first place, they have valued very positively the relevance of the project. Secondly, it has 
helped them to use international statistical portals that they had never used before. Thirdly, 
it has helped them to reflect on the difference between prices and costs, and how this 
difference translates into the profit margin. The comparison of prices and costs in the tables 
above shows that there are treatments that, if effective in combating Covid-19, could be 
moderately expensive (less than $30 for a standard course of treatment). However, in many 
cases, the differences between prices and costs are stratospheric. 
Fourthly, they have carried out an in-depth reflection on the existing disparities in access to 
medicines. In this situation, they considered, by an overwhelming majority, that although 
patents aim to promote knowledge by creating a monopoly around the product or innovation 
developed, in the particular case of the Covid-19 pandemic, health should be prioritised, and 
therefore, there should be a free transfer of technology, not only at the level of medicines 
developed, but of all the trials carried out. It is essential that generic medicines are accessible 
to all people, because the health of some is good for the health of all (positive externality). 
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